RxDoctor Payments Data

Julie Chacko, MD

Urology · Santa Barbara, CANPI 1225020571

Payments from drug & device makers

$12,058in general payments, 2019–2025

Across 469 payments — averaging $25.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Coloplast$1K
  • Astellas Pharma US Inc$794
  • Johnson & Johnson$558
  • Endo Pharmaceuticals Inc.$538
  • Boston Scientific$400
  • plus $7K from 54 others

What the payments were for

  • Speaking & faculty fees$1061%
  • Food & beverage$11,01091%
  • Education$9428%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,058 in reported general payments places this provider in the 75th percentile of 1,324 urology providers in California.

See all urology providers in California

Medicare billing

Part B allowed, 2024
$706,280
Medicare patients
1,272
Services billed
48,331

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron209$173,706
GemtesaVibegron173$170,471
Estradiol131$8,549
Mirabegron ErMirabegron11$7,410
Potassium Citrate ErPotassium Citrate71$7,124
Tamsulosin Hcl326$5,766
Silodosin47$3,972
Fesoterodine Fumarate ErFesoterodine Fumarate30$2,675
Oxybutynin Chloride ErOxybutynin Chloride74$2,548
Methenamine Hippurate31$2,469
Dutasteride41$2,285
Cimetidine23$1,987
Finasteride144$1,942
Solifenacin Succinate26$1,227
Testosterone Cypionate23$752

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$794$173,706209 claims
Sumitomo Pharma America, Inc.Gemtesa$389$170,471173 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,324 urology providers in California.

Other urology in Santa Barbara

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →